Publications by authors named "Busard C"
Article Synopsis
- The study investigates how combining methotrexate with adalimumab treatment affects drug concentration and response in psoriasis patients.
- A population PK-PD model was created from data collected over 49 weeks from 59 patients, revealing that methotrexate cotreatment reduces the development of antidrug antibodies, which can enhance the effectiveness of adalimumab.
- Overall, the findings suggest that using methotrexate alongside adalimumab can lead to better treatment outcomes by increasing adalimumab levels and potentially improving clinical responses.
Article Synopsis
- Anti-drug antibodies (ADA) can form in patients treated with adalimumab (ADL), potentially reducing its effectiveness; using methotrexate (MTX) alongside ADL seems to lower ADA levels and improve outcomes in rheumatologic diseases.
- A study was conducted in the Netherlands and Belgium to compare the long-term effectiveness and safety of ADL combined with MTX versus ADL alone over three years in patients with moderate to severe plaque psoriasis.
- Results showed no significant difference in drug survival between the two groups, even though the ADL + MTX group had a trend towards longer survival; however, adverse events led to common discontinuation in the combination group.
Article Synopsis
- Adalimumab is often used with methotrexate (MTX) for better treatment of rheumatoid arthritis and this study aimed to explore its effectiveness for chronic plaque psoriasis.
- The trial compared two groups: one receiving adalimumab alone and the other receiving adalimumab with MTX, analyzing factors like drug survival, response rates, and levels of antidrug antibodies.
- Results showed that the combination therapy led to fewer antidrug antibodies and a trend towards improved treatment response and drug survival, with no significant safety issues reported.
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Methods: To investigate the role of ustekinumab serum concentrations, anti-ustekinumab antibodies [AUA] and HLA-Cw6 status as tools for optimizing ustekinumab treatment, a multicenter prospective cohort study was conducted at an academic hospital with affiliated nonacademic hospitals in Belgium (cohort 1) and 2 academic hospitals in the Netherlands (cohort 2 and 3).
Results of clinical trials are the most important information source for generating external clinical evidence. The use of different outcomes across trials, which investigate similar interventions for similar patient groups, significantly limits the interpretation, comparability and clinical application of trial results. Core outcome sets (COSs) aim to overcome this limitation.
View Article and Find Full Text PDFBackground: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes.
Objective: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice.
Background: Harmonization of outcome measures is needed to increase the value of clinical trials on nail psoriasis.
Objectives: To provide the first step in core outcome set (COS) development for nail psoriasis.
Methods: A systematic review was performed to identify outcome instruments and corresponding outcome domains used in (ongoing) randomized controlled trials.
Background: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue to experience persistent disease activity or treatment failure over time. Strategies to optimize treatment outcomes include the use of concomitant methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment efficacy in psoriasis and other inflammatory diseases.
View Article and Find Full Text PDFImportance: Combined use of systemic agents may be necessary to achieve disease control in therapy-resistant patients. However, to our knowledge, an overview of evidence, including quality assessments, is not yet available, and no guidance on monitoring, contraindications, and interactions exists.
Objectives: To summarize and critically appraise the evidence on efficacy and safety of combination therapy with systemic agents in plaque-type psoriasis.